HUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated Tumors

/PRNewswire/ -- HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, announced today the FDA...

Related Keywords

China ,Japan ,Ireland ,Canada ,South Korea ,Bob Goodenow ,Yiota Merianos ,Kuifeng Wang ,Mireille Gillings ,Corporate Communications ,Investigational New Drug ,Huyabio International ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,Fda Approval ,